Literature DB >> 20131403

Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.

Carlo Spirli1, Stefano Okolicsanyi, Romina Fiorotto, Luca Fabris, Massimiliano Cadamuro, Silvia Lecchi, Xin Tian, Stefan Somlo, Mario Strazzabosco.   

Abstract

UNLABELLED: Polycystic liver disease may complicate autosomal dominant polycystic kidney disease (ADPKD), a disease caused by mutations in polycystins, which are proteins that regulate signaling, morphogenesis, and differentiation in epithelial cells. The cystic biliary epithelium [liver cystic epithelium (LCE)] secretes vascular endothelial growth factor (VEGF), which promotes liver cyst growth via autocrine and paracrine mechanisms. The expression of insulin-like growth factor 1 (IGF1), insulin-like growth factor 1 receptor (IGF1R), and phosphorylated mammalian target of rapamycin (p-mTOR) and the protein kinase A (PKA)-dependent phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) are also up-regulated in LCE. We have hypothesized that mammalian target of rapamycin (mTOR) represents a common pathway for the regulation of hypoxia-inducible factor 1 alpha (HIF1alpha)-dependent VEGF secretion by IGF1 and ERK1/2. Conditional polycystin-2-knockout (Pkd2KO) mice were used for in vivo studies and to isolate cystic cholangiocytes [liver cystic epithelial cells (LCECs)]. The expression of p-mTOR, VEGF, cleaved caspase 3 (CC3), proliferating cell nuclear antigen (PCNA), IGF1, IGF1R, phosphorylated extracellular signal-regulated kinase, p-P70S6K, HIF1alpha, and VEGF in LCE, LCECs, and wild-type cholangiocytes was studied with immunohistochemistry, western blotting, or enzyme-linked immunosorbent assays. The cystic area was measured by computer-assisted morphometry of pancytokeratin-stained sections. Cell proliferation in vitro was studied with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium and bromodeoxyuridine assays. The treatment of Pkd2KO mice with the mTOR inhibitor rapamycin significantly reduced the liver cyst area, liver/body weight ratio, pericystic microvascular density, and PCNA expression while increasing expression of CC3. Rapamycin inhibited IGF1-stimulated HIF1alpha accumulation and VEGF secretion in LCECs. IGF1-stimulated LCEC proliferation was inhibited by rapamycin and SU5416 (a vascular endothelial growth factor receptor 2 inhibitor). Phosphorylation of the mTOR-dependent kinase P70S6K was significantly reduced by PKA inhibitor 14-22 amide and by the mitogen signal-regulated kinase inhibitor U1026.
CONCLUSION: These data demonstrate that PKA-dependent up-regulation of mTOR has a central role in the proliferative, antiapoptotic, and pro-angiogenic effects of IGF1 and VEGF in polycystin-2-defective mice. This study also highlights a mechanistic link between PKA, ERK, mTOR, and HIF1alpha-mediated VEGF secretion and provides a proof of concept for the potential use of mTOR inhibitors in ADPKD and conditions with aberrant cholangiocyte proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20131403      PMCID: PMC2930014          DOI: 10.1002/hep.23511

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  35 in total

1.  Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma.

Authors:  Wei Wang; Wei-Dong Jia; Ge-Liang Xu; Zhi-Hua Wang; Jian-Sheng Li; Jin-Liang Ma; Yong-Sheng Ge; Sheng-Xue Xie; Ji-Hai Yu
Journal:  Dig Dis Sci       Date:  2008-12-04       Impact factor: 3.199

2.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

Review 3.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.

Authors:  M Hidalgo; E K Rowinsky
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

4.  A Cre recombinase transgene with mosaic, widespread tamoxifen-inducible action.

Authors:  Caiying Guo; Wenyi Yang; Corrinne G Lobe
Journal:  Genesis       Date:  2002-01       Impact factor: 2.487

5.  Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease.

Authors:  Domenico Alvaro; Paolo Onori; Gianfranco Alpini; Antonio Franchitto; Douglas M Jefferson; Alessia Torrice; Vincenzo Cardinale; Fabrizio Stefanelli; Maria Grazia Mancino; Mario Strazzabosco; Mario Angelico; Adolfo Attili; Eugenio Gaudio
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

6.  Store-operated cyclic AMP signalling mediated by STIM1.

Authors:  Konstantinos Lefkimmiatis; Meera Srikanthan; Isabella Maiellaro; Mary Pat Moyer; Silvana Curci; Aldebaran M Hofer
Journal:  Nat Cell Biol       Date:  2009-03-15       Impact factor: 28.824

7.  ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.

Authors:  Carlo Spirli; Stefano Okolicsanyi; Romina Fiorotto; Luca Fabris; Massimiliano Cadamuro; Silvia Lecchi; Xin Tian; Stefan Somlo; Mario Strazzabosco
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

Review 8.  The RSK factors of activating the Ras/MAPK signaling cascade.

Authors:  Audrey Carriere; Hind Ray; John Blenis; Philippe P Roux
Journal:  Front Biosci       Date:  2008-05-01

9.  The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growth of prostate cancer cells (DU145).

Authors:  Joanna Kisielewska; Janusz Ligeza; Andrzej Klein
Journal:  Folia Histochem Cytobiol       Date:  2008       Impact factor: 1.698

10.  Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.

Authors:  Gianfranco Distefano; Manila Boca; Isaline Rowe; Claas Wodarczyk; Li Ma; Klaus B Piontek; Gregory G Germino; Pier Paolo Pandolfi; Alessandra Boletta
Journal:  Mol Cell Biol       Date:  2009-03-02       Impact factor: 4.272

View more
  54 in total

1.  Inhibition of the P2X7 receptor reduces cystogenesis in PKD.

Authors:  Ming-Yang Chang; Jenn-Kan Lu; Ya-Chung Tian; Yung-Chang Chen; Cheng-Chieh Hung; Yi-Hui Huang; Yau-Hung Chen; Mai-Szu Wu; Chih-Wei Yang; Yi-Chuan Cheng
Journal:  J Am Soc Nephrol       Date:  2011-06-02       Impact factor: 10.121

Review 2.  Polycystic liver diseases: congenital disorders of cholangiocyte signaling.

Authors:  Mario Strazzabosco; Stefan Somlo
Journal:  Gastroenterology       Date:  2011-04-22       Impact factor: 22.682

Review 3.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

4.  Biliary infection may exacerbate biliary cystogenesis through the induction of VEGF in cholangiocytes of the polycystic kidney (PCK) rat.

Authors:  Xiang Shan Ren; Yasunori Sato; Kenichi Harada; Motoko Sasaki; Norihide Yoneda; Zhen Hua Lin; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2011-10-18       Impact factor: 4.307

5.  Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).

Authors:  Anna S Nikonova; Alexander Y Deneka; Anna A Kiseleva; Vladislav Korobeynikov; Anna Gaponova; Ilya G Serebriiskii; Meghan C Kopp; Harvey H Hensley; Tamina N Seeger-Nukpezah; Stefan Somlo; David A Proia; Erica A Golemis
Journal:  FASEB J       Date:  2018-01-10       Impact factor: 5.191

Review 6.  Regulation of biliary proliferation by neuroendocrine factors: implications for the pathogenesis of cholestatic liver diseases.

Authors:  Md Kamruzzaman Munshi; Sally Priester; Eugenio Gaudio; Fuquan Yang; Gianfranco Alpini; Romina Mancinelli; Candace Wise; Fanyn Meng; Antonio Franchitto; Paolo Onori; Shannon S Glaser
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

7.  Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice.

Authors:  Romina Fiorotto; Roberto Scirpo; Michael Trauner; Luca Fabris; Rafaz Hoque; Carlo Spirli; Mario Strazzabosco
Journal:  Gastroenterology       Date:  2011-06-26       Impact factor: 22.682

Review 8.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

9.  Primary cilia disruption differentially affects the infiltrating and resident macrophage compartment in the liver.

Authors:  Kurt A Zimmerman; Cheng Jack Song; Nancy Gonzalez-Mize; Zhang Li; Bradley K Yoder
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-15       Impact factor: 4.052

10.  Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease.

Authors:  Romina Mancinelli; Antonio Franchitto; Shannon Glaser; Antonella Vetuschi; Julie Venter; Roberta Sferra; Luigi Pannarale; Francesca Olivero; Guido Carpino; Gianfranco Alpini; Paolo Onori; Eugenio Gaudio
Journal:  Lab Invest       Date:  2016-08-29       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.